Portal de Periódicos da CAPES

P500. Evolution after anti-TNF drug discontinuation in patients with inflammatory bowel disease (IBD): a multicenter long-term follow-up study.

2015; Oxford University Press; Volume: 9; Issue: suppl 1 Linguagem: Inglês

10.1093/ecco-jcc/jju027.618

1876-4479

María José Casanova, María Chaparro, Valle García-Sánchez, Óscar Nantes, Aranzazu Jauregui-Amezaga, M Rojas-Feria, Juan A. Pineda, Joan Toscá, Pilar Martínez-Montiel, Lara Luzón, Ramón Pajares, Belén Beltrán, Manuel Barreiro–de Acosta, Laura Ramos, Isabel Pérez‐Martínez, F Bermejo, Yago González‐Lama, Manuel Domínguez‐Cajal, José María Huguet, Beatriz Sicilia, Carmen Dueñas-Sadornil, Ángel Ponferrada-Díaz, Olga Merino, Xavier Calvet, M Menacho, Jordi Guardiola, Patricia Ramírez de la Piscina, J L Pérez-Calle, Mercedes Domínguez-Antonaya, Marta Piqueras, Luis Fernández‐Salazar, David Busquets, José Manuel Benítez-Cantero, Cristina Rodríguez, Javier P. Gisbert,

Biosimilars and Bioanalytical Methods

IFX intensification (p>0.05).However, the sum of health care costs related to Crohn's disease was substantially lower (31%) for patients randomized to algorithm-based interventions than IFX intensification in the ITT population: €8,652 vs. €12,490; p<0.01.In the PP and PPw12 populations, costs at week 20 were even lower (49% and 50%) in the algorithm group: €6,335 vs. €12,490; p<0.01; and €6,171 vs. €12,364; p<0.01.In the PPCw20 population, costs were reduced by 60% in algorithm-treated patients: €5,113 vs. €12,881; p<0.001.The observed relative cost reductions (i.e.percentages) remained stable from week 20 until reassessment after one year, and were similar also when evaluating total health care costs irrespective of relation to Crohn's disease.Conclusions: Economic benefit of algorithm-based interventions at IFX failure is maintained throughout one year.